Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) EBIT (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed EBIT for 15 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT fell 42.54% to $4.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $16.3 million, a 110.7% increase, with the full-year FY2025 number at $16.3 million, up 110.7% from a year prior.
  • EBIT was $4.1 million for Q4 2025 at Niagen Bioscience, down from $4.2 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $7.1 million in Q4 2024 to a low of -$8.8 million in Q3 2021.
  • A 5-year average of -$1.4 million and a median of -$1.3 million in 2022 define the central range for EBIT.
  • Peak YoY movement for EBIT: plummeted 110.7% in 2021, then skyrocketed 4332.74% in 2024.
  • Niagen Bioscience's EBIT stood at -$5.3 million in 2021, then surged by 72.84% to -$1.4 million in 2022, then soared by 88.37% to -$168000.0 in 2023, then surged by 4332.74% to $7.1 million in 2024, then tumbled by 42.54% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's EBIT are $4.1 million (Q4 2025), $4.2 million (Q3 2025), and $3.2 million (Q2 2025).